Trial Profile
Open-label, Non-randomized, Two-stage Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Patients With Progressive Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Bimiralisib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors PIQUR Therapeutics
- 08 May 2018 Status changed from active, no longer recruiting to discontinued.
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2016 New trial record